Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16473210 | 0.87 | SLC6A9 (0.52) | TRPV1SLC6A9MTNR1AMTNR1BNPY5R | |
| SCHEMBL17399096 | 0.87 | SLC6A9 (0.52) | TRPV1SLC6A9MTNR1AMTNR1BNPY5R | |
| SCHEMBL16659175 | 0.87 | SLC6A9 (0.52) | TRPV1SLC6A9MTNR1AMTNR1BNPY5R | |
| SCHEMBL9854669 | 0.86 | TRPV1 (0.53) | TRPV1SLC6A9MTNR1AMTNR1BNPY5R | |
| SCHEMBL15617046 | 0.85 | TRPV1 (0.54) | TRPV1SLC6A9MTNR1AMTNR1BNPY5R | |
| SCHEMBL15617246 | 0.85 | TRPV1 (0.54) | TRPV1SLC6A9MTNR1AMTNR1BNPY5R | |
| SCHEMBL15544456 | 0.85 | TRPV1 (0.54) | TRPV1SLC6A9MTNR1AMTNR1BNPY5R | |
| SCHEMBL17399094 | 0.79 | TRPV1 (0.43) | TRPV1SLC6A9NPY5R | |
| SCHEMBL15544742 | 0.79 | TRPV1 (0.52) | TRPV1SLC6A9MTNR1AMTNR1BNPY5R | |
| SCHEMBL17399093 | 0.76 | SLC6A9 (0.42) | TRPV1SLC6A9NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145197-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | ABBVIE INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145197-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | ABBVIE INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145197-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | ABBVIE INC. | 2016-05-26 | — | — | US | disclosed |
| US-9227901-B2 | Process for preparing bicyclic amine derivatives | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227901-B2 | Process for preparing bicyclic amine derivatives | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227901-B2 | Process for preparing bicyclic amine derivatives | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2870132-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | AbbVie Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20140012015-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | ABBVIE INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2014008350-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | ABBVIE INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014008350-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | ABBVIE INC. (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145197-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | HRH4, HRH3, HRH1 | TRPV1 3747/4885SLC6A9 2885/4885MTNR1A 3378/4885 |
| US-20140012015-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | HRH4, HRH3, HRH1 | TRPV1 3747/4885SLC6A9 2885/4885MTNR1A 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.